The Ras/Raf signaling pathway has been recognized as an important process in cancer biology. Recently, activating mutations in the BRAF gene were reported to be present in ~66% of malignant melanomas as well as other malignancies such as colon cancer. Here, the authors report the development of a B-Raf-specific cellular assay to profile cell-active B-Raf inhibitors. Expression of the active B-Raf mutant (V600E) and the kinase-inactive form of its substrate, MEK1, was regulated by mifepristone, and the catalytic activity of B-Raf was monitored by following MEK1 phosphorylation. Target specificity was ensured because the phosphorylation of MEK1 was significantly inhibited when kinase-inactive B-Raf was used in place of the active kinase. A cellular c-Raf assay was similarly established to monitor the selectivity between B-Raf and c-Raf. Z′ factor values were consistently above 0.50 with either kinase, indicating that assay performance was sufficiently robust for use as cellular profiling assays. The authors used this system to demonstrate that the selectivity profile of compounds targeted against B-Raf and c-Raf kinases could be quantitatively determined. This platform provides a quantitative cellular readout for a spectrum of specific inhibitors of B-Raf and c-Raf kinases that is particularly suitable for use in drug discovery. (Journal of Biomolecular Screening 2007:818-827)
Marais R. , Light Y. , Paterson HF , Mason CS , Marshall CJ : Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases . J Biol Chem1997;272: 4378-4383 .
2.
Davies H. , Bignell GR , Cox C. , Stephens P. , Edkins S. , Clegg S. , et al: Mutations of the BRAF gene in human cancer . Nature2002;417: 949-954 .
3.
Kimura ET , Nikiforova MN , Zhu Z. , Knauf JA , Nikiforov YE , Fagin JA : High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma . Cancer Res2003;63: 1454-1457 .
4.
Rajagopalan H. , Bardelli A. , Lengauer C. , Kinzler KW , Vogelstein B. , Velculescu VE : Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status . Nature2002;418: 934 .
5.
Garnett MJ , Marais R. : Guilty as charged: B-RAF is a human oncogene. CancerCell2004;6: 313-319 .
6.
Kolch W. : Meaningful relationships: the regulation of the Ras/Raf/ MEK/ERK pathway by protein interactions . Biochem J2000;351(pt 2): 289-305 .
7.
Hall-Jackson CA , Eyers PA , Cohen P. , Goedert M. , Boyle FT , Hewitt N. , et al: Paradoxical activation of Raf by a novel Raf inhibitor . Chem Biol1999;6: 559-568 .
8.
Hall-Jackson CA , Goedert M. , Hedge P. , Cohen P. : Effect of SB 203580 on the activity of c-Raf in vitro and in vivo . Oncogene1999;18: 2047-2054 .
9.
Wilhelm SM , Carter C. , Tang L. , Wilkie D. , McNabola A. , Rong H. , et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis . Cancer Res2004;64: 7099-7109 .
10.
McCubrey JA , Steelman LS , Hoyle PE , Blalock WL , Weinstein-Oppenheimer C. , Franklin RA , et al: Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells . Leukemia1998;12: 1903-1929.
11.
Lewis TS , Shapiro PS , Ahn NG : Signal transduction through MAP kinase cascades . Adv Cancer Res1998;74: 49-139 .
12.
Hazen RJ , Harvey RJ , St Clair MH , Ferris RG , Freeman GA , Tidwell JH , et al: Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance . Antimicrob Agents Chemother2005;49: 4465-4473 .
13.
Takle AK , Brown MJ , Davies S. , Dean DK , Francis G. , Gaiba A. , et al: The identification of potent and selective imidazole-based inhibitors of B-Raf kinase . Bioorg Med Chem Lett2006 ;16: 378-381 .
14.
King AJ , Patrick DR , Batorsky RS , Ho ML , Do HT , Zhang SY , et al: Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885 . Cancer Res2006;66: 11100-11105 .
15.
Dean DK , Takle AK , Wilson DM : Imidazole derivatives as Raf kinase inhibitors. W002/24680 2002.
16.
Alessi DR , Cuenda A. , Cohen P. , Dudley DT , Saltiel AR : PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo . J Biol Chem1995;270: 27489-27494 .
17.
Favata MF , Horiuchi KY , Manos EJ , Daulerio AJ , Stradley DA , Feeser WS , et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase . J Biol Chem1998;273: 18623-18632 .
18.
Mason CS , Springer CJ , Cooper RG , Superti-Furga G. , Marshall CJ , Marais R. : Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation . Embo J1999;18: 2137-2148 .
19.
Senner V. , Sotoodeh A. , Paulus W. : Regulated gene expression in glioma cells: a comparison of three inducible systems . Neurochem Res2001;26: 521-524 .
20.
Abruzzese RV , Godin D. , Mehta V. , Perrard JL , French M. , Nelson W. , et al: Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system . Mol Ther2000;2: 276-287 .
21.
Ravi RK , Weber E. , McMahon M. , Williams JR , Baylin S. , Mal A. , et al: Activated Raf-1 causes growth arrest in human small cell lung cancer cells . J Clin Invest1998;101: 153-159 .
22.
Wan PT , Garnett MJ , Roe SM , Lee S. , Niculescu-Duvaz D. , Good VM , et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF . Cell2004;116: 855-867 .
23.
Dhillon AS , Meikle S. , Peyssonnaux C. , Grindlay J. , Kaiser C. , Steen H. , et al: A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation . Mol Cell Biol2003;23: 1983-1993.
24.
Adler V. , Qu Y. , Smith SJ , Izotova L. , Pestka S. , Kung HF , et al: Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway . Biochemistry2005;44: 10784-10795 .
25.
Terai K. , Matsuda M. : Ras binding opens c-Raf to expose the docking site for mitogen-activated protein kinase kinase . EMBO Rep2005;6: 251-255 .
26.
Chong H. , Lee J. , Guan KL : Positive and negative regulation of Raf kinase activity and function by phosphorylation . Embo J2001;20: 3716-3727 .
27.
Cohen P. : The development and therapeutic potential of protein kinase inhibitors . Curr Opin Chem Biol1999;3: 459-465 .
28.
Knight ZA , Shokat KM : Features of selective kinase inhibitors . Chem Biol2005;12: 621-637 .
29.
Cheng Y. , Prusoff WH : Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction . Biochem Pharmacol1973;22: 3099-3108 .
30.
Davies SP , Reddy H. , Caivano M. , Cohen P. : Specificity and mechanism of action of some commonly used protein kinase inhibitors . Biochem J2000;351: 95-105 .
31.
Newbatt Y. , Burns S. , Hayward R. , Whittaker S. , Kirk R. , Marshall C. , et al: Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen . J Biomol Screen2006;11: 145-154 .
32.
Menjivar M. , Ortiz G. , Cardenas M. , Garza-Flores J. : Comparison of the DELFIA and RIA methods for measuring luteinizing and follicle stimulating hormones in serum [in Spanish] . Rev Invest Clin1993;45: 579-584 .
